Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Afluria Quadrivalent in Adults
NCT02214225Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated) in influenza (3 arms), sponsored by CSL Seqirus. Primary endpoints: Geometric Mean Titer at 21 days and Seroconversion Rate at 21 days. Started Aug 2014; status: completed.
02
Drugs
influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02214225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214225.